Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01995695 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01995695 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants.
The verdict
NCT01995695, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
H7N9 avian influenza (AI) viruses have caused a recent outbreak of severe respiratory disease in humans in China. The purpose of this study is to evaluate the safety and immunogenicity of a live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine in healthy adults. A single dose of inactivated subvirion H7N9 influenza vaccine will be administered 3 months later.
Interventions
- BIOLOGICAL Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine
- BIOLOGICAL Inactivated subvirion H7N9 influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01995695
The ClinicalTrials.gov registry entry for NCT01995695 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine is the first listed.
NCT01995695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01995695 about?
NCT01995695 is a clinical study titled "Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults". H7N9 avian influenza (AI) viruses have caused a recent outbreak of severe respiratory disease in humans in China. The purpose of this study is to evaluate the safety and immunogenicity of a live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine in healthy adults. A single dose of inactivated sub...
What is the current status of trial NCT01995695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-10.
What interventions are being tested in trial NCT01995695?
The interventions under investigation include: Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine (BIOLOGICAL), Inactivated subvirion H7N9 influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01995695?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.